TheraCryf PLC (TCF)

Industry Biotechnology


This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

0.17p

Buy

0.20p

arrow-up0.015p (+8.11%)

Prices updated at 16 Sep 2026, 11:38 BST
| Prices minimum 15 mins delay
|
Prices in GBX

TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 ...

logo In the news

Sharecast service unavailable

logo Press releases

14 Sep 2026

11 Sep 2026

10 Sep 2026

07 Sep 2026

20 Aug 2026

26 May 2026

15 May 2026

15 May 2026

14 May 2026

16 Apr 2026

logo Key dates

Forecast date
Half yearly resultsDec 2026
Annual general meetingOct 2026
Final resultsSep 2026
Annual reportSep 2026
Previous date
Half yearly resultsDec 2025
Annual general meetingJul 2025
Annual reportJun 2025
Final resultsJun 2025

logo Company reports



Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.